Real-time Early Detection of Nephrotoxicity by Urinary Biomarker Analysis With SeroFlow Technology - Trial NCT06124885
Access comprehensive clinical trial information for NCT06124885 through Pure Global AI's free database. This phase not specified trial is sponsored by National University Hospital, Singapore and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National University Hospital, Singapore
Timeline & Enrollment
N/A
Nov 01, 2023
Dec 01, 2024
Primary Outcome
Presence of an Acute kidney injury (AKI) event
Summary
The study aims to perform real-time validation of the RenaFAST kit (a point-of-care test kit
 that quantifies three urinary proteins) in predicting acute kidney injury(AKI) among patients
 prescribed drug therapies of nephrotoxic potential. Based on the type and duration of drug
 therapy, a maximum of 5 time-point urine samples will be collected from consenting patients
 and a real-time biomarker analysis will be conducted using the RenaFAST kits.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06124885
Non-Device Trial